Core Insights - IMUNON, Inc. announced positive results from its Phase 1 proof-of-concept clinical trial for IMNN-101, a DNA plasmid vaccine targeting the SARS-CoV-2 Omicron XBB1.5 variant, demonstrating safety and immunogenicity [2][3][4] Group 1: Clinical Trial Results - The Phase 1 trial involved 24 healthy volunteers and showed that IMNN-101 induced a persistent 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4, with further increases observed between Week 2 and Week 4 [2][4] - No serious adverse effects were reported, indicating an acceptable safety profile for IMNN-101 [2][3] - The immune response was effective against the XBB1.5 variant and other newer variants, showcasing the vaccine's cross-reactivity [2][3] Group 2: Technology and Development - IMNN-101 is based on the proprietary PlaCCine technology platform, which allows for flexible manufacturing and stable storage conditions, making it a potential alternative to mRNA vaccines [5][6] - The vaccine demonstrated strong immunogenicity in preclinical studies, with over 95% protection in non-human primates, comparable to existing mRNA vaccines [5] - The PlaCCine platform's design accommodates single or multiple antigens, enhancing its potential for developing vaccines against various infectious diseases [6] Group 3: Future Prospects - The company anticipates interest from potential partners for further development of IMNN-101 based on the strong immunogenicity evidence and competitive advantages in stability [3][5] - IMUNON is also advancing its lead clinical program, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, indicating a broader focus on innovative treatments [10]
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19